First Manhattan CO Arvinas, Inc. Transaction History

First Manhattan CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$58.19 - $91.37 $5.49 Million - $8.63 Million	-94,400 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $1.89 Million - $7.95 Million	93,616 Added 11940.82%	94,400 $8.02 Million
Q1 2020 May 06, 2020	BUY	$33.0 - $54.5 $12,111 - $20,001	367 Added 88.01%	784 $31,000
Q4 2019 Feb 13, 2020	BUY	$15.39 - $44.38 $6,417 - $18,506	417 New	417 $17,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.01B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.